Blogs
For two decades, the global outsourcing conversation had two default answers: WuXi for speed and scale, Lonza for biologics and regulatory pedigree.
For almost two decades, ICH Q2(R1) was the only reference point for validating analytical methods. That changed in late 2023. ICH Q2(R2)
Process Safety in Pharmaceutical Scale-Up: Managing Exothermic Reactions and Hazardous Intermediates
A reaction that runs smoothly in a 500 mL flask can behave very differently in a 500 L reactor. Heat that dissipates
Most molecules die in early discovery for one of two reasons. Either the chemistry never worked well enough to advance. Or it
The Wrong CRO Will Cost You More Than Money You will lose time, definitely. You might also lose the candidate entirely. Most
Choosing a contract API manufacturer is one of the highest-stakes decisions a procurement or CMC team makes. Get it right, and your
You have a promising small molecule. The biology looks good. The medicinal chemistry team is excited. Now comes the part that separates
Early drug discovery risk is the most common. Mitigating the risk is uncertain. And most of the time, it fails. According to
LAXAI: Your Trusted Partner in Supplying High-Quality Starting Materials for Commercial Pharmaceuticals LAXAI: Your Trusted Partner in Supplying High-Quality Starting Materials for
How To Ease The Transition From IND-Enabling Studies To GMP Production How To Ease The Transition From IND-Enabling Studies To GMP Production
Navigating Regulatory Challenges in Drug Development Navigating Regulatory Challenges in Drug Development Regulatory compliance in drug development is complex and can significantly
The Future of Green Chemistry – Innovations in Specialty Chemicals The Future of Green Chemistry – Innovations in Specialty Chemicals Chemistry, Manufacturing,
Chemistry, Manufacturing & Control (CMC) Chemistry, Manufacturing & Control (CMC) Introduction to CMC Chemistry, Manufacturing, and Controls (CMC) form the backbone of
Seamless CRDMO Transition: RSM from Clinical trials to Commercial Supply Chain Seamless CRDMO Transition: RSM from Clinical trials to Commercial Supply Chain









